The retrospective multicentre ELEVATE study in the United States involved 14 myologists and neurologists who prescribed eculizumab to 119 of their patients suffering from Myasthenia Gravis, with anti-RACh in 97% of cases. This drug, prescribed most often for inadequate symptom control (82%) or poor tolerance of treatment (40%), resulted in:
- a significant reduction in the MG-ADL score, from a mean value of 8 before eculizumab to 5.4 after three months of treatment, then 4.7 at 24 months;
- a clear increase in the proportion of patients achieving minimal manifestation or remission status, from 5% to 43% at six months, 36% at 12 months and 30% at 24 months;
- clinical improvement in 70% of patients at 24 months.
Anti-C5 also often enabled corticosteroid therapy to be reduced (64% of cases) or even stopped (13%), or other immunosuppressants to be discontinued (32%). Taken together, these results consolidate those already published from the REGAIN trial and its open-label extension.
